TP53 and neoplasm: We used a p53 mutant derivative of MCF10A for these experiments, for two reasons: (a) to better model tumour cells with p53 pathway dysfunction; and (b) so that in later CRISPR‐Cas9 genetic screens, mutations that often impair cellular fitness by invoking p53‐mediated cell cycle checkpoints are better tolerated.